Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more
Shandong Realcan Pharmaceutical Co Ltd (002589) - Total Liabilities
Latest total liabilities as of September 2025: CN¥9.87 Billion CNY
Based on the latest financial reports, Shandong Realcan Pharmaceutical Co Ltd (002589) has total liabilities worth CN¥9.87 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shandong Realcan Pharmaceutical Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Shandong Realcan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shandong Realcan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Realcan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Plejd AB
ST:PLEJD
|
Sweden | Skr327.09 Million |
|
Three's Company Media Group Co Ltd
SHG:605168
|
China | CN¥1.46 Billion |
|
LAMDA Development S.A.
AT:LAMDA
|
Greece | €3.10 Billion |
|
Bank Tabungan Negara Persero
JK:BBTN
|
Indonesia | Rp491.58 Trillion |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
USA | $119.80 Million |
|
Shenzhen Sunxing Light Alloys
SHG:603978
|
China | CN¥2.54 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Shandong Realcan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Realcan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Realcan Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total liabilities of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥10.32 Billion | -6.82% |
| 2023-12-31 | CN¥11.07 Billion | -11.98% |
| 2022-12-31 | CN¥12.58 Billion | -24.69% |
| 2021-12-31 | CN¥16.70 Billion | -22.84% |
| 2020-12-31 | CN¥21.65 Billion | -2.54% |
| 2019-12-31 | CN¥22.21 Billion | -5.60% |
| 2018-12-31 | CN¥23.53 Billion | +35.94% |
| 2017-12-31 | CN¥17.31 Billion | +112.27% |
| 2016-12-31 | CN¥8.15 Billion | +49.42% |
| 2015-12-31 | CN¥5.46 Billion | +41.64% |
| 2014-12-31 | CN¥3.85 Billion | +37.40% |
| 2013-12-31 | CN¥2.80 Billion | +27.24% |
| 2012-12-31 | CN¥2.20 Billion | +57.38% |
| 2011-12-31 | CN¥1.40 Billion | +18.34% |
| 2010-12-31 | CN¥1.18 Billion | +46.87% |
| 2009-12-31 | CN¥805.78 Million | +33.49% |
| 2008-12-31 | CN¥603.64 Million | -- |